Yissum Ltd. Signs a Collaboration Agreement with Aurum Ventures MKI for the Development of Breakthrough Liver-Bypassing Oral Drug Delivery Nanotechnology
6/15/2009 9:43:30 AM
TEL AVIV, Israel--(BUSINESS WIRE)--Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today at the ILSI-Biomed Israel 2009 conference, it has signed an agreement with Aurum, Ventures MKI, the technology investment arm of Mr. Morris Kahn, for the development of a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administered lipophilic drugs. The technology was developed by Prof. Simon Benita at the Hebrew University's School of Pharmacy.
comments powered by